δ-carbolines and their ring-opened analogs: Synthesis and evaluation against fungal and bacterial opportunistic pathogens

European Journal of Medicinal Chemistry

Volumn 46, Issue 6, 2011, Pages 2378-2385

  Mazu, Tryphon K ^a   Etukala, Jagan R ^a   Jacob, Melissa R ^b   Khan, Shabana I ^b   Walker, Larry A ^b   Ablordeppey, Seth Y ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

carboline; Anti bacterial; Anti fungal; Opportunistic; Quaternary; Synthesis

Indexed keywords

5 (5 CYCLOHEXYLPENTYL) 1 METHYL 5H PYRIDO [3,2 B]INDOL 1 IUM IODIDE; 5 (5 CYCLOHEXYLPENTYL) 1 METHYL 8 (METHYLTHIO) 5H PYRIDO [3,2 B]INDOL 1 IUM IODIDE; 5 (5 CYCLOHEXYLPENTYL) 1 METHYL 8 (TRIFLUOROMETHYL) 5H PYRIDO [3,2 B]INDOL 1 IUM IODIDE; 5 (5 CYCLOHEXYLPENTYL) 1,8 DIMETHYL 5H PYRIDO [3,2 B]INDOL 1 IUM IODIDE; 5 (5 CYCLOHEXYLPENTYL) 8 FLUORO 1 METHYL 5H PYRIDO [3,2 B]INDOL 1 IUM IODIDE; 5 (5 CYCLOHEXYLPENTYL) 8 METHOXY 1 METHYL 5H PYRIDO [3,2 B]INDOL 1 IUM IODIDE; 6 CHLORO 5 (5 CYCLOHEXYLPENTYL) 1 METHYL 5H PYRIDO [3,2 B]INDOL 1 IUM IODIDE; 7 CHLORO 5 (5 CYCLOHEXYLPENTYL) 1 METHYL 5H PYRIDO [3,2 B]INDOL 1 IUM IODIDE; 8 CHLORO 5 (5 CYCLOHEXYLPENTYL) 1 METHYL 5H PYRIDO [3,2 B]INDOL 1 IUM IODIDE; 8 CYANO 5 (5 CYCLOHEXYLPENTYL) 1 METHYL 5H PYRIDO [3,2 B]INDOL 1 IUM IODIDE; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CARBOLINE DERIVATIVE; CIPROFLOXACIN; CRYPTOLEPINE; DELTA CARBOLINE DERIVATIVE; DOXORUBICIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CANDIDA KRUSEI; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SYNTHESIS; ESCHERICHIA COLI; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM INTRACELLULARE; STAPHYLOCOCCUS AUREUS; SUBSTITUTION REACTION; VERO CELL;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; BACTERIA; CARBOLINES; CERCOPITHECUS AETHIOPS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; FUNGI; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; VERO CELLS;

EID: 79955611731     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.03.021     Document Type: Article

References (27)

1. L.G. Mardenborough, P. Fan, S.Y. Ablordeppey, A. Nimrod, A.M. Clark, Identification of a novel antifungal agent based on a pharmacophoric group in cryptolepine, Med. Chem. Res. 9 (1999) 118-132. (Pubitemid 29227493)
2. S.Y. Ablordeppey, P. Fan, A.M. Clark, A. Nimrod, Probing the N-5 region of the indolo-quinoline alkaloid, cryptolepine for anticryptococcal activity, Bioorg. Med. Chem. 7 (1999) 343-349.
3. T.K. Mazu, J.R. Etukala, S.K. Eyunni, X.Y. Zhu, M.R. Jacob, S.I. Khan, L.A. Walker, S.Y. Ablordeppey, Identification of 3-phenylaminoquinolinium and 3-phenylaminopyridinium salts as new agents against AIDS-related opportunistic pathogens, Bioorg. Med. Chem. 19 (2011) 524-533.
4. (a) H.W. Boucher, G.R. Corey, Epidemiology of methicillin-resistant Staphylococcus aureus, Clin. Infect. Dis. 46 (Suppl. 5) (2008) S344-S349;
5. (b) R.M. Klevens, M.A. Morrison, J. Nadle, S. Petit, K. Gershman, S. Ray, L.H. Harrison, R. Lynfield, G. Dumyati, J.M. Townes, A.S. Craig, E.R. Zell, G.E. Fosheim, L.K. McDougal, R.B. Carey, S.K. Fridkin, for the ABCs, Invasive methicillin-resistant Staphylococcus aureus infections in the United States, J. Amer. Med. Assoc. 298 (2007) 1763-1771.
6. P. Fan, S.Y. Ablordeppey, An alternative synthesis of 10H-indolo[3,2-b]quinoline and its selective N-alkylation, J. Heterocycl. Chem. 34 (1997) 1789-1794.
7. E.V. Kumar, J.R. Etukala, S.Y. Ablordeppey, Indolo[3,2-b]quinolines: synthesis, biological evaluation and structure activity-relationships, Mini Rev. Med. Chem. 8 (2008) 538-554.
8. C.A. Boateng, S.V.K. Eyunni, X.Y. Zhu, J.R. Etukala, B.A. Bricker, M.K. Ashfaq, M.R. Jacob, S.I. Khan, L.A. Walker, S.Y. Ablordeppey, Benzothieno[3,2-b] quinolinium and 3-(phenylthio)-quinolinium compounds: synthesis and evaluation against opportunistic fungal pathogens, Bioorg. Med. Chem. 19 (2010) 458-470.
9. (a) S.Y. Ablordeppey, P. Fan, S. Li, A.M. Clark, C.D. Hufford, Substituted indoloquinolines as new antifungal agents, Bioorg. Med. Chem. 10 (2002) 1337-1346;
10. (b) X.Y. Zhu, L.G. Mardenborough, S. Li, A. Khan, W. Zhang, P. Fan, M.R. Jacob, S. Khan, L.A.Walker, S.Y. Ablordeppey, Synthesis and evaluation of isosteres of N-methyl indolo[3,2-b]-quinoline (cryptolepine) as new antiinfective agents, Bioorg. Med. Chem. 15 (2007) 686-695.
11. H. Van de Waterbeemd, S. Rose, in: C.G. Wermuth (Ed.), The Practice of Medicinal Chemistry, second ed. Elsevier Academic Press, 2004, p. 351.
12. L. Mardenborough, X.Y. Zhu, P. Fan, M.R. Jacob, S.I. Khan, L.A. Walker, S.Y. Ablordeppey, Identification of bis-quindolines as new antiinfective agents, Bioorg. Med. Chem. 13 (2005) 3951-3963.
13. (a) M.B. Navarro, B. Huttner, B.S. Harbarth, Methicillin-resistant Staphylococcus aureus control in the 21st century: beyond the acute care hospital, Curr. Opin. Infect. Dis. 21 (2008) 372-379;
14. (b) T.M. File Jr., Impact of community-acquired methicillin-resistant Staphylococcus aureus in the hospital setting, Cleve Clin. J. Med. 74 (Suppl 4) (2007) S6-S11.
15. G.M. Anstead, G. Quinones-Nazario, J.S. Lewis, Treatment of infections caused by resistant Staphylococcus aureus, Methods Mol. Biol. 391 (2007) 227-258.
16. M.E. Stryjewski, G.R. Corey, New treatments for methicillin-resistant Staphylococcus aureus, Curr. Opin. Crit. Care 15 (2009) 403-412.
17. (a) V. Cattoir, C. Daurel, Update on antimicrobial chemotherapy, Med. Mal Infect. 40 (2010) 135-154;
18. (b) A. Coates, Y. Hu, R. Bax, C. Page, The future challenges facing the development of new antimicrobial drugs, Nat. Rev. Drug Discov. 1 (2002) 895.
19. (a) C.B. Inderlied, C.A. Kemper, L.E. Bermudez, The Mycobacterium avium complex, Clin. Microbiol. Rev. 6 (1993) 266-310;
20. (b) K.B. MacDonell, J. Glassroth, Mycobacterium avium complex and other nontuberculous mycobacteria in patients with HIV infection, Semin. Respir. Infect. 4 (1989) 123-132.
21. (a) V. Samoylenko, M.R. Jacob, S.I. Khan, J. Zhao, B.L. Tekwani, J.O. Midiwo, L.A. Walker, I. Muhammad, Antimicrobial, antiparasitic and cytotoxic spermine alkaloids from Albizia schimperiana, Nat. Prod. Commun. 4 (2009) 791-796;
22. (b) M. Guoyi, S. Khan, M.R. Jacob, B.L. Tekwani, Z. Li, D.S. Pasco, L.A. Walker, I.A. Khan, Antimicrobial and antileishmanial activities of hypocrellins A and B, Antimicrob. Agents Chemother. 48 (2004) 4450-4452.
23. National Committee for Clinical Laboratory Standards, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically M7-A5. National Committee for Clinical Laboratory Standards, Wayne, PA, 2000.
24. National Committee for Clinical Laboratory Standards, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts Approved Standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, PA, 1997.
25. National Committee for Clinical Laboratory Standards, Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes Tentative Standard 3962 M24-T2, second ed.. National Committee for Clinical Laboratory Standards, Wayne, PA, 2000.
26. S.G. Franzblau, R.S. Witzig, J.C. McLaughlin, P. Torres, G. Madico, A. Hernandez, M.T. Degnan, M.B. Cook, V.K. Quenzer, R.M. Ferguson, R.H. Gilman, Rapid, lowtechnology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay, J. Clin. Microbiol. 36 (1998) 362-366. (Pubitemid 28060296)
27. J. Mustafa, S.I. Khan, G. Ma, L.A. Walker, I.A. Khan, Synthesis and in vitro cytotoxic activity of N-, F-, and S-ether derivatives of podophyllotoxin fatty acid adducts, Lipids 40 (2006) 375-382.